- Home
- GNPX
GNPX
Genprex Inc.
as 01-22-2025 4:00pm EST
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 6.1M | IPO Year: | 2018 |
| Target Price: | $10.00 | AVG Volume (30 days): | 367.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $13.00 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Genprex Inc. News
GNPX Breaking Stock News: Dive into GNPX Ticker-Specific Updates for Smart Investing
TipRanks
9 days ago
Genprex Advances Cancer Trials and Diabetes Therapy
PR Newswire
17 days ago
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
a month ago
Genprex Completes Phase 1 Dose Escalation in Trial of Reqorsa Gene Therapy to Treat Lung Cancer
PR Newswire
a month ago
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
Pharmaceutical Technology
2 months ago
Genprex links with University of Michigan on lung cancer treatment
MT Newswires
2 months ago
Genprex Signs License Deal for University of Michigan's Gene Therapy to Treat Lung Cancer
PR Newswire
2 months ago
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
MT Newswires
3 months ago
Genprex Reports Positive Preclinical Data on Reqorsa Gene Therapy; Regains Nasdaq Compliance
Compare GNPX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GNPX Genprex Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.